Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03215147
Other study ID # ILD Asthma
Secondary ID
Status Recruiting
Phase N/A
First received June 18, 2017
Last updated July 9, 2017
Start date June 7, 2017
Est. completion date February 28, 2020

Study information

Verified date July 2017
Source Seoul National University Hospital
Contact Choi Sun Mi
Phone 02-2072-4915
Email sunmich81@gmail.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The investigators assess the prevalence of airway disease associated with idiopathic pulmonary fibrosis in Korea, and evaluate the effect of these airway diseases on the symptoms and quality of life of patients with idiopathic pulmonary fibrosis.


Description:

Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, and limited to the lungs. It is characterized by progressive worsening of dyspnea and lung function and is associated with a poor prognosis.

The main symptoms of patients with IPF are dyspnea on exertion and a persistent dry cough or mildly productive cough.

In many IPF patients, cough is often the first symptom, preceding dyspnea on exertion sometimes by years. It affects upwards of 70-85% of patients with IPF.

Chronic obstructive pulmonary disease (prevalence rate 4-18%) and asthma (prevalence rate 5.9-9.9%) are the airway disease whose main symptoms are also dyspnea and cough.

To date, the effect of airway disease has not been well studied in patients with idiopathic pulmonary fibrosis, and the prevalence is unknown in Korea.

Unlike idiopathic pulmonary fibrosis, airway disease is a treatable, modifiable disease, so treatment of these diseases may improve QOL in IPF patients.

Therefore, this study's purpose is A. Identify the prevalence of airway disease in IPF patients B. Identify differences in QOL and symptoms according to presence of airway disease C. Identify the symptomatic improvement after active treatment for the airway diseases


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date February 28, 2020
Est. primary completion date February 28, 2020
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- IPF patients

Exclusion Criteria:

- Patients on systemic steroid

- Patients with acute exacerbation within the last 6 months

- PFT+BDR, MBPT contra-indication

- SpO2 < 90%

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Confirmation of Airway Disease combined with IPF
To confirm the airway disease combined with IPF, PFT+BDR+DLCO, MBPT, Induced sputum exam, MAST, Total IgE, serum Eosinophil count, FENO will be done at the time of registration and 6~8 weeks later.

Locations

Country Name City State
Korea, Republic of Seoul National University Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants who have asthma combined with idiopathic pulmonary fibrosis Confirmation of asthma : pulmonary function test with bronchodilator response or Methacholine provocation test Through study completion, an average of 2 year
Primary Number of participants who have COPD combined with idiopathic pulmonary fibrosis Confirmation of COPD : pulmonary function test with bronchodilator response Through study completion, an average of 2 year
Primary Number of participants who have Eosinophilic bronchitis combined with idiopathic pulmonary fibrosis Confirmation of Eosinophilic bronchitis : pulmonary function test with bronchodilator response, induced sputum Through study completion, an average of 2 year
Secondary The difference of CAT scores between patients with airway disease and those without airway disease. Quality of life : COPD assessment test(CAT) baseline and after treating the airway disease for 6~8 weeks
Secondary The difference of SGRQ scores to assess quality of life between patients with airway disease and those without airway disease. Quality of life : St George's Respiratory Questionnaire(SGRQ) baseline and after treating the airway disease for 6~8 weeks
Secondary The difference of mMRC scores to assess symptom severity between patients with airway disease and those without airway disease. Symptom severity : mMRC baseline and after treating the airway disease for 6~8 weeks
Secondary The difference of distance of 6MWT to assess symptom severity between patients with airway disease and those without airway disease. Symptom severity : 6 minute walking test(6MWT) baseline and after treating the airway disease for 6~8 weeks
Secondary The difference of EQ-5D-VAS scores to assess symptom severity between patients with airway disease and those without airway disease. Symptom severity : EQ-5D-VAS baseline and after treating the airway disease for 6~8 weeks
Secondary The difference of CQLQ scores to assess symptom severity between patients with airway disease and those without airway disease. Symptom severity : Cough Quality-of-Life Questionnaire(CQLQ) baseline and after treating the airway disease for 6~8 weeks
Secondary Checking the improvement of CAT score to assess the quality of life between patients with airway disease and those without airway disease Quality of life : COPD assessment test(CAT) After treating the airway disease for 6~8 weeks
Secondary Checking the improvement of SGRQ score to assess the quality of life between patients with airway disease and those without airway disease Quality of life : St George's Respiratory Questionnaire(SGRQ) After treating the airway disease for 6~8 weeks
Secondary Checking the improvement of mMRC scores to assess symptom severity between patients with airway disease and those without airway disease Symptom severity : mMRC After treating the airway disease for 6~8 weeks
Secondary Checking the improvement of distance of 6MWT to assess symptom severity between patients with airway disease and those without airway disease Symptom severity : 6 minute walking test(6MWT) After treating the airway disease for 6~8 weeks
Secondary Checking the improvement of EQ-5D-VAS score to assess symptom severity between patients with airway disease and those without airway disease Symptom severity : EQ-5D-VAS After treating the airway disease for 6~8 weeks
Secondary Checking the improvement of CQLQ to assess symptom severity between patients with airway disease and those without airway disease Symptom severity : Cough Quality-of-Life Questionnaire(CQLQ) After treating the airway disease for 6~8 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05984992 - The First-in-human Study of SRN-001 in Healthy Participants Phase 1
Active, not recruiting NCT04312594 - Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT03865927 - GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT03979430 - Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study N/A
Enrolling by invitation NCT04905693 - Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Phase 3
Not yet recruiting NCT06241560 - A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood Phase 2
Terminated NCT04419558 - Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 3
Completed NCT03725852 - A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Terminated NCT03573505 - An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT04148157 - Quality of Life in IPF - Patient and Physician Perceptions
Completed NCT03222648 - Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis N/A
Not yet recruiting NCT06422884 - A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) Phase 2
Completed NCT02268981 - Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF) N/A
Completed NCT02257177 - RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients Phase 1/Phase 2
Withdrawn NCT01524068 - A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations Phase 2
Enrolling by invitation NCT01382368 - Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Phase 4
Completed NCT01199887 - Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis Phase 1
Completed NCT01110694 - Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
Active, not recruiting NCT02951416 - Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
Terminated NCT00981747 - Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis Phase 2/Phase 3